| Objective to investigate the effect of atorvastatin in different dosages onserum cholesterin and CRP in ACS. Methods The levels of blood lipid and C-reactive protein(CRP) of 81ACSpatients including 41 acute myocardial infarction(AMI) patients and 40 unstableangina pectoris(UA) patients were measured before treatments after admission aswell as 30 stable angina pectoris(SA) patients and 30 patients without coronaryheart disease as control(C) group. After that, 81 ACS patients were dividedrandomly into two groups,one group treated with 10mg/d atorvastatin as A group,while another treated with 40mg/d atorvastatin as B group. The use of atorvastatinlasted from seven to ten days. And other treatments were the same in both A and Bgroup. Levels of blood lipid,CRP were measured again in these patients aftertreatment. Results ①Serum levels of total cholesterol(TC) in patients with UA exceptAMI and SA were significantly higher than those in patients withoutCHD(P<0.01),but no difference was found between serum levels of TC inpatients with AMI, UA and SA(P>0.05).②Serum levels of low-densitylipidprotein cholesterol(LDL-C) in patients with UA were significantly higher thanthose in patients without CHD(P<0.05)and patients with AMI(P<0.05).③Therewas no difference between serum significant high-density lipidprotein 4cholesterol(HDL-C) in AMI, UA, SA and C group patients(P>0.05).④ACSexcept SA patients had significantly higher serum CRP levels than those in Cgroup patients(P<0.05),and serum levels of CRP in AMI patients weresignificantly higher than those in UA and SA patients(P<0.05).⑤Both A and Bgroup of ACS patients had lower TC, LDL-C ,and CRP levels than beforeatorvastatin treatment,but there were a much stronger TC, LDL-C and CRPdecrease in patients taking 40mg/d atorvastatin(P<0.05). Conclusion ①Serum levels in ACS patients increase significantly, and levelsof CRP in patients with AMI are higher. ②Levels of TC and LDL-C in ACS arehigher comparing with patients without CHD, but have no significant differencefrom those in SA. As a result, blood cholesterol levels have not such a obviousrelation with CHD risk as CRP levels. ③It is proved in our study that atorvastatincan not only decrease blood lipid but also resist inflammation. Atorvastatin has amuch more significant blood TC, LDL-C and CRP decrease at 40mg/d than at10mg/d. And all patients could stand with atorvastatin at larger dosage withoutserious uncomfortable symptoms. Therefore we suggest that all ACS patientsshould take atorvastatin at larger dosage as early as possible. |
